L 734217

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596676

CAS#: 146144-48-1

Description: L 734217 is a fibrinogen receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

L 734217 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 596676
Name: L 734217
CAS#: 146144-48-1
Chemical Formula: C18H31N3O4
Exact Mass: 353.2315
Molecular Weight: 353.46
Elemental Analysis: C, 61.17; H, 8.84; N, 11.89; O, 18.11


Synonym: L 734217; L-734217; L734217; L-734,217; L 734,217; L734,217;

IUPAC/Chemical Name: (R)-3-(2-((R)-2-oxo-3-(2-(piperidin-4-yl)ethyl)piperidin-1-yl)acetamido)butanoic acid

InChi Key: SFFMYDBKYYBJRY-HIFRSBDPSA-N

InChi Code: InChI=1S/C18H31N3O4/c1-13(11-17(23)24)20-16(22)12-21-10-2-3-15(18(21)25)5-4-14-6-8-19-9-7-14/h13-15,19H,2-12H2,1H3,(H,20,22)(H,23,24)/t13-,15+/m1/s1

SMILES Code: C[C@@H](NC(CN1C([C@H](CCC2CCNCC2)CCC1)=O)=O)CC(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999 Jul 15;94(2):587-99. PubMed PMID: 10397726.

2: Prueksaritanont T, Stranieri MT, Hand EL, Ellis JD, Holahan MA, Sitko GR, Cook JJ. Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734,217, in dogs. Biopharm Drug Dispos. 1997 Nov;18(8):649-63. PubMed PMID: 9373723.

3: Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF 3rd, Wallace AA, Hand EL, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ, Lynch JJ Jr. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73. PubMed PMID: 8764336.

4: Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang CT, Cook JJ, Gould RJ, Ihle NC, Hartman GD, Lynch JJ, et al. Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J Med Chem. 1995 Aug 18;38(17):3332-41. PubMed PMID: 7650686.